Look back at pharma news in the week to March 26, 2021

28 March 2021

By Barbara Obstoj-Cardwell. Editor

Among last week’s notable news, AstraZeneca released long-waited data from the US Phase III trial of its COVID-1 vaccine, AZD1222, which pave the way for US regulatory approval and restore confidence in Europe, but this was not without further controversy. Roche and Regeneron Pharmaceuticals reported strong Phase III data for their REGN-COV2 antibody cocktail for hospitalized COVID-19 patients. Pfizer and Eli Lilly suffered a setback on their osteoarthritis pain drug tanezumab, with a negative Food and Drug Administration advisory committee vote. Dutch rare diseases firm ProQR Therapeutics announced encouraging early-stage results for its QR-421a in Usher syndrome, a rare blindness disorder.

AstraZeneca silences its COVID-19 vaccine doubters

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK